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Abstract Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to
kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity
and suggests that applying CAR strategies to other immune cell lineages may be beneficial. Here,
we engineered a family of Chimeric Antigen Receptors for Phagocytosis (CAR-Ps) that direct
macrophages to engulf specific targets, including cancer cells. CAR-Ps consist of an extracellular
antibody fragment, which can be modified to direct CAR-P activity towards specific antigens. By
screening a panel of engulfment receptor intracellular domains, we found that the cytosolic
domains from Megf10 and FcRV robustly triggered engulfment independently of their native
extracellular domain. We show that CAR-Ps drive specific engulfment of antigen-coated synthetic
particles and whole human cancer cells. Addition of a tandem PI3K recruitment domain increased
cancer cell engulfment. Finally, we show that CAR-P expressing murine macrophages reduce cancer
cell number in co-culture by over 40%.
DOI: https://doi.org/10.7554/eLife.36688.001
Introduction
Chimeric antigen receptors (CARs) are synthetic transmembrane receptors that redirect T cell activity
towards clinically relevant targets (reviewed in [Lim et al., 2017; Fesnak et al., 2016]). The CAR-T
receptor contains an extracellular single chain antibody fragment (scFv) that recognizes known tumor
antigens, and intracellular signaling domains from the T Cell Receptor (TCR) and costimulatory mole-
cules that trigger T cell activation (Fesnak et al., 2016; Kochenderfer et al., 2009). CAR-T cells rec-
ognizing CD19, a marker expressed at high levels on the surface of B cells and B cell-derived
malignancies, have been used successfully to target hematological malignancies with 70–90% of
patients showing measurable improvement (Lim et al., 2017; Engel et al., 1995; Haso et al., 2013).
The success of CAR-T suggests that programming immune cells to target cancer might be a broadly
applicable approach.
Macrophages are critical effectors of the innate immune system, responsible for engulfing debris
and pathogens. Harnessing macrophages to combat tumor growth is of longstanding interest
(Alvey and Discher, 2017; Lee et al., 2016). Macrophages are uniquely capable of penetrating solid
tumors, while other immune cells, like T cells, are physically excluded or inactivated (Lim et al.,
2017; Lee et al., 2016). This suggests that engineered macrophages may augment existing T cell-
based therapies. Early efforts transferring healthy macrophages into cancer patients failed to inhibit
tumor growth, suggesting that macrophages require additional signals to direct their activity
towards tumors (Lacerna et al., 1988; Andreesen et al., 1990). Antibody blockade of CD47, a neg-
ative regulator of phagocytosis, reduced tumor burden, indicating that shifting the balance in favor
of macrophage activation and engulfment is a promising therapeutic avenue (Majeti et al., 2009;
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Chao et al., 2010; Jaiswal et al., 2009; Tseng et al., 2013). Here, we report a family of chimeric
antigen receptors that activate phagocytosis of cancer cells based on recognition of defined cell sur-
face markers, resulting in significantly reduced cancer cell growth.
Results
To program engulfment towards a target antigen, we created a CAR strategy using the CAR-T
design as a guide (Fesnak et al., 2016). We call this new class of synthetic receptors Chimeric Anti-
gen Receptors for Phagocytosis (CAR-Ps). The CAR-P molecules contain the extracellular single-
chain antibody variable fragment (scFv) recognizing the B cell antigen CD19 (aCD19) and the CD8
transmembrane domain present in the aCD19 CAR-T (Fesnak et al., 2016; Kochenderfer et al.,
2009). To identify cytoplasmic domains capable of promoting phagocytosis, we screened a library of
known murine phagocytic receptors: Megf10 (Figure 1a), the common V subunit of Fc receptors
(FcRV), Bai1, and MerTK (Penberthy and Ravichandran, 2016). FcR triggers engulfment of anti-
body-bound particles, while the other receptors recognize apoptotic corpses (Freeman and Grin-
stein, 2014; Penberthy and Ravichandran, 2016). We also made a receptor containing an
extracellular aCD19 antibody fragment and a cytoplasmic GFP, but no signaling domain, to test
whether adhesion mediated by the aCD19 antibody fragment is sufficient to induce engulfment
(Figure 1a; CAR-PGFP).
To assay our library of CAR-Ps, we introduced each CAR-P into J774A.1 murine macrophages by
lentiviral infection. As an engulfment target, we used 5 mm diameter silica beads coated with a sup-
ported lipid bilayer. A His8-tagged extracellular domain of CD19 was bound to a NiNTA-lipid incor-
porated into the supported lipid bilayers. Macrophages expressing a CAR-P with the Megf10 (CAR-
PMegf10) or FcRV (CAR-PFcRV) intracellular domain promoted significant engulfment of CD19 beads
compared to macrophages with no CAR (Figure 1b,c, Figure 1—video 1). Macrophages expressing
CAR-PBai1, CAR-PMerTK, and the adhesion-only CAR-PGFP did not bind the CD19 beads even though
these CAR-Ps are present at the cell surface (Figure 1b,c, Figure 1—figure supplement 1). To con-
firm that the CAR-P was a viable strategy for redirecting primary macrophages, we expressed the
CAR-PFcRV in primary murine bone marrow derived macrophages and found that these transfected
primary cells also were able to trigger engulfment of CD19 beads (Figure 1d).
Next we asked if the CAR-P strategy could target a different antigen. Because CAR-PMegf10 per-
formed well in our initial screen (Figure 1a), we developed aCD22 CAR-PMegf10 using a previously
developed aCD22 antibody fragment (Xiao et al., 2009; Haso et al., 2013). Consistent with our
results using aCD19-based CARs, aCD22 CAR-PMegf10 promoted engulfment of CD22 beads
(Figure 2a). To confirm antigen specificity of CAR-P, we incubated aCD19 CAR-PMegf10
eLife digest Our immune system constantly patrols our body, looking to eliminate cancerous
cells and harmful microbes. It can spot these threats because it recognizes certain signals at the
surface of dangerous cells. However, cancer cells often find ways to ‘hide’ from our immune system.
Chimeric antigen receptors, or CARs, are receptors designed in a laboratory to attach to specific
proteins that are found on a cancer cell. These receptors tell immune cells, such as T cells, to attack
cancers. T cells that carry CARs are already used to treat people with blood cancers. Yet, these
immune cells are not good at penetrating a solid tumor to kill the cells inside, which limits their use.
Macrophages are a group of immune cells that can make their way inside tumors and travel to
cancers that the rest of the immune system cannot reach. They defend our body by ‘swallowing’
harmful cells. Would it then be possible to use CARs to program macrophages to ‘eat’ cancer cells?
Morrissey, Williamson et al. created a new type of CARs, named CAR-P, and introduced it in
macrophages. These cells were then able to recognize and attack beads covered in proteins found
on cancer cells. The modified macrophages could also limit the growth of live cancer cells in a dish
by ‘biting’ and even ‘eating’ them. While these results are promising in the laboratory, the next step
is to test whether these reprogrammed macrophages can recognize and fight cancers in living
animals.
DOI: https://doi.org/10.7554/eLife.36688.002
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Figure 1. Identification of intracellular signaling region for CAR-P. (A) Schematics show the structure of CAR-P constructs. An aCD19 (purple) or aCD22
(blue, center) scFv directs CAR specificity. Intracellular signaling domains from Megf10 or the indicated engulfment receptor (green) activate
engulfment. CAR-PGFP contains only GFP and no intracellular signaling domains (right). All constructs include a transmembrane domain from CD8 and a
C-terminal GFP. (B) J774A.1 macrophages expressing aCD19 CAR-P with the indicated intracellular signaling domain (green) engulf 5 mm silica beads
Figure 1 continued on next page
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macrophages with CD22 beads, and aCD22 CAR-PMegf10 macrophages with CD19 beads. CD19
beads were not eaten by aCD22 CAR-PMegf10 macrophages, and CD22 beads were not eaten by
aCD19 CAR-PMegf10 macrophages (Figure 2a). These data indicate that CAR-PMegf10 specifically
Figure 1 continued
covered with a supported lipid bilayer containing His-tagged CD19 extracellular domain. The beads were visualized with atto390-labeled lipid
incorporated into the supported lipid bilayer (magenta). Cells infected with the cell membrane marker, mCherry-CAAX, were used as a control (no CAR,
top left). To the right of each image is a histogram depicting the frequency of cells engulfing the indicated number of beads. The average number of
beads eaten per cell is quantified in (C). (D) Bone marrow derived macrophages were infected with CAR-PFcRV or GFP-CAAX (green, left and center top;
grey, center bottom) and incubated with CD19 beads (magenta) for 45 min. Images show an x-y plane through the center of the engulfed beads (left),
or a cross section (center) of the z plane indicated in the inset panel (white line). The histogram depicts the number of cells engulfing the indicated
number of beads. The scale bar indicates 5 mm and n = 78–163 cells per condition, collected during three separate experiments. Error bars denote 95%
confidence intervals and *** indicates p<0.0001 compared to mCherry-CAAX control by Kruskal-Wallis test with Dunn’s multiple comparison correction.
DOI: https://doi.org/10.7554/eLife.36688.003
The following video and figure supplement are available for figure 1:
Figure supplement 1. Expression level of CAR-P constructs in macrophages.
DOI: https://doi.org/10.7554/eLife.36688.004
Figure 1—video 1. CAR-PMegf10 macrophage engulfs silica beads
DOI: https://doi.org/10.7554/eLife.36688.005
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Figure 2. CAR-P expression drives specific engulfment of diverse beads. (A) Macrophages infected with the aCD19 (purple) or aCD22 (blue) CAR-
PMegf10 or mCherry-CAAX control were fed 5 mm beads ligated with either CD19 (left) or CD22 (right). Engulfment is quantified as the mean beads
eaten per cell. The fraction of phagocytic cells is as follows: 31/144 GFP-CAAX cells engulfed CD19 beads, 87/149 aCD19 CAR-PMegf10 engulfed CD19
beads, 20/142 aCD22 CAR-PMegf10 engulfed CD19 beads, 28/140 GFP-CAAX cells engulfed CD22 beads, 18/151 aCD19 CAR-PMegf10 engulfed CD22
beads, 103/148 aCD22 CAR-PMegf10 engulfed CD22 beads (pooled data was collected during three separate experiments). Error bars denote 95%
confidence intervals and *** indicates p<0.0001 compared to mCherry-CAAX control by Kruskal-Wallis test with Dunn’s multiple comparison correction.
(B) J774A.1 macrophages expressing the aCD19 CAR-PMegf10 (green) were fed beads of various sizes (magenta, diameter of bead indicated below
image). The beads were covered in a supported lipid bilayer ligated to His-tagged CD19 extracellular domain and the number of beads engulfed per
cell is reported below each image (magenta bars indicate CAR-PMegf10 macrophages and pink bars indicate CAR-PGFP). The aCD19 CAR-PMegf10
macrophages were also incubated with 10 mm beads coated in phosphatidylserine (PS) and ICAM-1 (blue bar in graph, 51/390 cells engulfed a bead).
The fraction of cells engulfing a CD19 bead is as follows: 135/169 CAR-PMegf10 and 134/187 CAR-PGFP cells engulfed 2.5 um bead, 126/395 CAR-PMegf10
and 112/499 CAR-PGFP cells engulfed a 5 um bead, 48/377 CAR-PMegf10 and 21/378 CAR-PGFP cells engulfed a 10 um bead, 120/706 CAR-PMegf10 and
45/675 CAR-PGFP cells engulfed a 15 um bead, 194/760 CAR-PMegf10 and 23/587 CAR-PGFP cells engulfed a 20 um bead (data is pooled from at least
three separate experiments). Error bars denote 95% confidence intervals of the mean. *** indicates p<0.0001 respectively by Mann-Whitney test. All
scale bars represent 5 mm.
DOI: https://doi.org/10.7554/eLife.36688.006
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triggers engulfment in response to the target ligand and that the CAR-P strategy is able to target
multiple cancer antigens.
To further define the capabilities of the CAR-P, we assessed the capacity of CAR-P-expressing
macrophages to engulf variably sized targets. We found that CAR-PMegf10 was able to trigger spe-
cific engulfment of beads ranging from 2.5 mm to 20 mm in diameter, with higher specificity above
background engulfment being demonstrated for the larger beads (Figure 2b). The high background
in this assay is due to heterogeneity in the bilayers on beads purchased from a different manufac-
turer (Corpuscular) than previous assays. For the 10 mm bead condition, we also tested the phago-
cytic efficiency of beads containing the endogenous Megf10 ligand, phosphatidylserine. We found
that CAR-PMegf10 macrophages engulfed CD19 beads and beads containing 10% phosphatidylserine
and the adhesion molecule ICAM-1 at a similar frequency (Figure 2b). This indicates that the CAR-P
is comparably efficient to the endogenous system.
To determine if the CAR-PMegf10 initiates active signaling at the synapse between the macro-
phage and target, we stained for phosphotyrosine. Macrophages expressing CAR-PMegf10 exhibited
an increase in phosphotyrosine at the synapse, while macrophages expressing CAR-PGFP did not
show this enrichment (Figure 3a). Consistent with previous reports, we found that F-actin also was
enriched at the cell bead synapse (Figure 3—figure supplement 1). This result suggests that CAR-
PMegf10 initiates engulfment through a localized signaling cascade involving tyrosine
phosphorylation.
Both successful CAR-P intracellular domains (from FcRV and Megf10) have cytosolic Immunore-
ceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by Src family kinases.
Based on this observation, we hypothesized that the expression of an alternate ITAM-containing
receptor might initiate phagocytosis when expressed in macrophages. The CD3z subunit of the T
cell receptor contains three ITAM motifs. To test if the CD3z chain was able to activate phagocytic
signaling, we transduced macrophages with the first generation CAR-T (Figure 3b). The CAR-T was
able to trigger engulfment of CD19 beads to a comparable extent as CAR-PMegf10 (Figure 3c). In T
cells, phosphorylated ITAMs in CD3z bind to tandem SH2 domains (tSH2) in the kinase ZAP70.
Zap70 is not expressed in macrophages, but Syk, a phagocytic signaling effector and tSH2 domain
containing protein, is expressed at high levels (Andreu et al., 2017). Previous work suggested that
Syk kinase can also bind to the CD3z ITAMs (Bu et al., 1995), indicating that the CAR-T may pro-
mote engulfment through a similar mechanism as CAR-PFcRV. To quantitatively compare the interac-
tion between SyktSH2 and CD3z or FcRV in a membrane proximal system recapitulating physiological
geometry, we a used liposome-based assay (Figure 3d [Hui and Vale, 2014]). In this system, His10-
CD3z and His10-Lck (the kinase that phosphorylates CD3z) are bound to a liposome via NiNTA-lipids
and the binding of labeled tandem SH2 domains to phosphorylated CD3z was measured using fluo-
rescence quenching. Our results show that Syk-tSH2 binds the CD3z and FcRV with comparable
affinity (~15 nM and ~30 nM respectively, Figure 3d). Collectively, these results demonstrate that
the TCR CD3z chain can promote phagocytosis in a CAR-P, likely through the recruitment of Syk
kinase.
We next sought to program engulfment towards a cellular target. We incubated the CAR-PMegf10
and CAR-PFcRV macrophages with cancerous Raji B cells that express high levels of endogenous
CD19. Strikingly, the majority of CAR-P-expressing macrophages internalized bites of the target cell
(Figure 4a, Figure 4—video 1, 78% of CAR-PMegf10 and 85% of CAR-PFcRV macrophages internal-
ized bites within 90 min). The biting phenotype resembles trogocytosis, or nibbling of live cells,
which has been reported previously in immune cells (Joly and Hudrisier, 2003). This process was
dependent on the ITAM-bearing intracellular signaling domain, as removing the signaling domain
(CAR-PGFP) dramatically reduced trogocytosis (Figure 4a). Enrichment of phosphotyrosine at the
cell-cell synapse further supports active signaling initiating trogocytosis (Figure 4—figure supple-
ment 1). The CAR-P module also was able to induce trogocytosis in non-professional phagocytes,
human NIH 3T3 fibroblast cells (Figure 4—figure supplement 2). This suggests that the CAR-P can
promote cancer antigen-dependent engulfment by both professional and non-professional
phagocytes.
We next focused on engineering strategies to engulf whole human cancer cells. We observed
that macrophages expressing the CAR-PMegf10 or CAR-PFcRV were capable of engulfing whole Raji B
cells (2 cancer cells eaten per 100 macrophages in a 4–8 hr window for both CAR-PMegf10 or CAR-
PFcRV, Figure 4b,e, Figure 4—video 2). Whole cell engulfment was infrequent but trogocytosis was
Morrissey et al. eLife 2018;7:e36688. DOI: https://doi.org/10.7554/eLife.36688 5 of 21
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robust, suggesting that productive macrophage target interactions were frequently insufficient to
trigger whole cell engulfment. To determine if whole cell eating could be enhanced by further opso-
nization of CD19, we opsonized Raji B cells with a mouse IgG2a anti-CD19 antibody. While addition
of this antibody did not trigger additional whole cell internalization, blockade of the ‘don’t eat me’
signal CD47 using the mouse IgG1 anti-human B6H12 clone resulted in a 2.5 fold increase of whole
cell eating of opsonized Raji B cells (Figure 4—figure supplement 3). Both endogenous FcR recog-
nition of the anti-CD47 antibody and blockade of CD47 signaling may contribute to this effect.
To develop a receptor to enhance whole cell eating, we hypothesized that combining signaling
motifs in a tandem array might increase the frequency of whole cell engulfment by specifically
recruiting effectors required for the engulfment of large targets. Previous work demonstrated that
PI3K signaling is important for internalization of large targets (Schlam et al., 2015). To increase PI3K
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Figure 3. A phosphorylated ITAM at the cell-target synapse drives engulfment. (A) Macrophages expressing aCD19 CAR-PMegf10 (green, top) or aCD19
CAR-PGFP were incubated with CD19-ligated beads (position indicated with dotted line), fixed and stained for phosphotyrosine (magenta, top;
greyscale, bottom). The fold enrichment of phosphotyrosine at the cell-bead synapse compared to the cell cortex is graphed on the right (n  11; each
dot represents one cell-bead synapse; lines represent the mean ±one standard deviation). (B) Schematic shows the structure of CAR-P constructs in the
plot at right. An aCD19 (purple) scFv directs CAR specificity. The intracellular signaling domains from CD3z activate engulfment. On the right is a
histogram depicting the fraction of macrophages engulfing the indicated number of CD19-coated beads. (C) Comparison showing the average number
of beads eaten per cell in J774A.1 macrophages expressing aCD19 CAR-Ps with the indicated intracellular signaling domain. 5 mm silica beads covered
with a supported lipid bilayer containing His-tagged CD19 extracellular domain were used as an engulfment target (n = 156–167 cells per condition
collected during three separate experiments). Error bars denote 95% confidence intervals and *** indicates p<0.0001 compared to CAR-PGFP control by
Kruskal-Wallis test with Dunn’s multiple comparison in correction. (D) Model of the liposome-based fluorescence quenching assay used to determine
affinity between the Syk tSH2 domains and the receptor tails of CD3z and FcRV, two intracellular signaling domains that promote engulfment. Binding
between the Syk tSH2 reporter (Syk tSH2), green, and a receptor tail, purple, was detected by rhodamine quenching of BG505 dye on the reporter (see
Materials and methods). Kd was determined by assessing mean fluorescence quenching for the last 20 timepoints collected ~45 min after ATP addition
over a receptor titration from 0 to 500 nM. Each point represents the mean ± SD from three independent experiments. Kd ± SE was calculated by
nonlinear fit assuming one site specific binding.
DOI: https://doi.org/10.7554/eLife.36688.007
The following figure supplement is available for figure 3:
Figure supplement 1. F-actin is enriched at the cell-target synapse.
DOI: https://doi.org/10.7554/eLife.36688.008
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Figure 4. CAR-P promotes trogocytosis and whole cell eating. (A) J774A.1 macrophages expressing the aCD19 CAR-PMegf10 (top panel, green in
merge, left; greyscale, center) engulf pieces of CD19 +Raji B cells (labeled with mCherry-CAAX; magenta in merge, left; greyscale, right). The
corresponding control aCD19 CAR-PGFP-infected cells are shown below. Arrows point to pieces of ingested Raji B cell. The proportion of CAR-P
expressing macrophages internalizing one or more bite within 90 min is quantified on the right. Bites are defined as a fully internalized mCherry-
positive vesicle >1 mm in diameter; n = 46 CAR-PMegf10 macrophages, n = 39 CAR-PFcRV macrophages and 102 CAR-PGFP macrophages acquired during
three separate experiments. (B) Time course of a J774A.1 macrophage expressing CAR-PFcRV (green) internalizing a whole Raji B cell labeled with
mCherry-CAAX (magenta). These images correspond to frames from Figure 4—video 2. (C) Schematic shows the structure of CAR-Ptandem construct,
combining the intracellular signaling domain from FcRV and the p85 recruitment domain from CD19. (D) Time course of a J774A.1 macrophage
expressing CAR-Ptandem (green) internalizing a whole Raji B cell labeled with mCherry-CAAX (magenta). These images correspond to frames from
Figure 4—video 3. (E) Macrophages and Raji B cells were incubated together at a 1:2 macrophage:Raji ratio, and the number of whole Raji B cells
eaten per 100 macrophages during 4–8 hr of imaging is graphed. Graph depicts pooled data from four independent experiments; n = 921 CAR-PGFP,
n = 762 CAR-PFcRV, n = 638 CAR-PPI3K, n = 555 CAR-Ptandem cells. Sample sizes were selected for their ability to detect a 5% difference between
samples with 95% confidence. (F) 10,000 macrophages and 20,000 Raji B cells were incubated together for 44 hr. The number of Rajis was then
Figure 4 continued on next page
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recruitment to the CAR-P, we fused the portion of the CD19 cytoplasmic domain (amino acids 500
to 534) that recruits the p85 subunit of PI3K to the CAR-PFcRV creating a ‘tandem’ CAR (CAR-Ptandem,
Figure 4c) (Tuveson et al., 1993; Brooks et al., 2004). A CAR-P containing the p85 recruitment
motif alone (CAR-PPI3K) was able to induce some whole cell engulfment, comparable to the CAR-
PFcRV (Figure 4e). Expression of CAR-Ptandem tripled the ability of macrophages to ingest whole cells
compared to CAR-PGFP (6 cancer cells eaten per 100 macrophages, Figure 4d,e, Figure 4—video
3). These data indicate that assembling an array of motifs designed to recruit distinct phagocytic
effectors can increase CAR-P activity towards whole cells.
To determine if the combination of whole cell eating and trogocytosis was sufficient to drive a
noticeable reduction in cancer cell number, we incubated CAR-P macrophages with Raji B cells for
two days. After 44 hr of co-culture, we found that CAR-P macrophages significantly reduced the
number of Raji cells (Figure 4f). Although the CAR-Ptandem was much more efficient at whole cell
eating, the CAR-PFcRV performed nearly as well at eliminating Rajis. Importantly, our assay does not
distinguish between whole cell engulfment or death following trogocytosis, so it is possible both
CAR-P activities are contributing to Raji death rates. Overall, these data suggest that the CAR-P is a
successful strategy for directing macrophages towards cancer targets, and can initiate whole cell eat-
ing and trogocytosis leading to cancer cell elimination.
In summary, we engineered phagocytes that recognize and ingest targets through specific anti-
body-mediated interactions. This strategy can be directed towards multiple extracellular ligands
(CD19 and CD22) and can be used with several intracellular signaling domains that contain ITAM
motifs (Megf10, FcRV, and CD3z). Previous work has suggested that spatial segregation between
Src-family kinases and an inhibitory phosphatase, driven by receptor ligation, is sufficient to trigger
signaling by the T cell receptor (Davis and van der Merwe, 2006; James and Vale, 2012) and FcR
(Freeman et al., 2016). The CAR-Ps that we have developed may similarly convert receptor-ligand
binding into receptor phosphorylation of ITAM domains through partitioning of kinases and phos-
phatases at the membrane-membrane interface.
Further development of CAR-Ps could be useful on several therapeutic fronts. Targeting of tumor
cells by macrophages has been suggested to cause tumor cell killing (Jaiswal et al., 2009;
Majeti et al., 2009; Chao et al., 2010; Jadus et al., 1996), either through directly engulfing cancer
cells or by stimulating antigen presentation and a T cell-mediated response (Liu et al., 2015;
Tseng et al., 2013). Inhibition of the CD47-SIRPA ‘Don’t eat me’ signaling pathway has also been
shown to result in engulfment of cancer cells (Chen et al., 2017; Gardai et al., 2005; Jaiswal et al.,
Figure 4 continued
quantified by FACS. 2–3 technical replicates were acquired each day on three separate days. The number of Rajis in each replicate was normalized to
the average number present in the GFP-CAAX macrophage wells on that day. * indicates p<0.01, *** indicates p<0.0001 by two-tailed Fisher Exact Test
(a and e) or by Ordinary one way ANOVA with Dunnet’s correction for multiple comparisons (f); error bars denote 95% confidence intervals.
DOI: https://doi.org/10.7554/eLife.36688.009
The following video and figure supplements are available for figure 4:
Figure supplement 1. CAR-P localizes with pTyr at synapse with Raji B cell.
DOI: https://doi.org/10.7554/eLife.36688.010
Figure supplement 2. NIH 3T3 cells internalize Raji B cell bites.
DOI: https://doi.org/10.7554/eLife.36688.011
Figure supplement 3. Opsonization by an anti-CD47 antibody enhances whole cell internalization through CAR-P Macrophages expressing CAR-PFcRV
and Raji B cells were incubated together at a 1:2 macrophage:Raji ratio (20,000 macrophages and 40,000 Rajis) without antibody addition (No ab) or in
the presence of anti-CD19 or anti-CD47 antibodies as indicated.
DOI: https://doi.org/10.7554/eLife.36688.012
Figure supplement 4. CAR-P promotes internalization of cancer antigen.
DOI: https://doi.org/10.7554/eLife.36688.013
Figure 4—video 1. CAR-PMegf10 macrophage engulfs bites of a Raji B cell.
DOI: https://doi.org/10.7554/eLife.36688.014
Figure 4—video 2. CAR-PFcRV macrophage engulfs a Raji B cell.
DOI: https://doi.org/10.7554/eLife.36688.015
Figure 4—video 3. CAR-Ptandem macrophage engulfs a Raji B cell.
DOI: https://doi.org/10.7554/eLife.36688.016
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2009; Majeti et al., 2009; Chao et al., 2010). A recent study suggests that CD47 inhibition is most
effective when combined with a positive signal to promote target engulfment, which raises the pos-
sibility of combining CAR-P expression with CD47 or SIRPA inhibition for an additive effect
(Alvey et al., 2017).
Although we were able to increase whole cell engulfment by recruiting the activating subunit of
PI3K to the phagocytic synapse, the engulfment of larger 20 micron beads was more frequent than
the engulfment of whole cells. We hypothesize that this is due to differing physical properties of the
engulfment target. Specifically, increased target stiffness has been shown to promote engulfment,
suggesting that manipulating the physical properties of the engulfment target could also be a
potential strategy for increasing CAR-P efficiency (Beningo and Wang, 2002; Cross et al., 2007).
While the CAR-P can engulf whole, viable cancer cells, the ingestion of a piece of the target cell
is more common. Trogocytosis, or nibbling of living cells, has also been described in immune cells
(Harshyne et al., 2003; Harshyne et al., 2001; Kao et al., 2006; Joly and Hudrisier, 2003;
Batista et al., 2001) and brain-eating amoebae (Ralston et al., 2014). In vivo studies also have
shown that endogenous dendritic cell populations ingest bites of live tumor cells, contributing to
presentation of cancer neo-antigen (Harshyne et al., 2001; Harshyne et al., 2003). Although we
were able to use the CAR-P to induce trogocytosis in dendritic cells, we were not able to detect
robust cross presentation of the model antigen ovalbumin (Figure 4—figure supplement 4). Thus,
although using CAR-Ps to enhance cross presentation of cancer antigen is an intriguing future ave-
nue, such a strategy would likely require more optimization of the dendritic cell subset employed or
the CAR-P receptor itself.
Overall, our study demonstrates that the CAR approach is transferrable to biological processes
beyond T cell activation and that the expression of an engineered receptor in phagocytic cells is suf-
ficient to promote specific engulfment and elimination of cancer cells.
Materials and methods
Key resources table
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Cell line
(Mus musculus)
J774A.1 Macrophages UCSF Cell Culture
Facility
Cell line
(Homo sapiens)
Raji B Cells Other Obtained from M. McManus,
UCSF
Cell line
(Mus musculus)
3t3 Fibroblasts UCSF Cell Culture
Facility
Cell line
(Mus musculus)
C57BL/6J PMID: 21356739 Bone Marrow Derived
Macrophages (BMDM)
Cell line
(Mus musculus)
C57BL/6J PMID: 7489412 Bone Marrow derived
Dendritic Cells (BMDC)
Cell line
(Homo sapiens)
HEK293T cells UCSF Cell Culture
Facility
Lentivirus production
Genetic Reagent
(Mus musculus)
OTI PMID: 8287475 E. Roberts/M. Krummel Lab UCSF
Recombinant
DNA reagent
CD19-mMegf10 CAR this paper Signal peptide: aa 1–21 CD8
(Uniprot Q96QR6_HUMAN)
Extracellular antibody sequence: V-L
chain: aa 23–130 anti-CD19
CAR (Genbank AMZ04819) – GS linker:
ggtggcggtggctcgggcggtggtgggtcgggt
ggcggcggatct – V-H chain: aa 148–267
anti-CD19 CAR (Genbank AMZ04819)
Stalk/Transmembrane: aa 138–206 CD8
(Uniprot Q96QR6_HUMAN)
Cytosolic sequence: aa 879–1147 Mouse
Megf10 (Uniprot Q6DIB5 (MEG10_MOUSE))
Fluorophore: mGFP
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Recombinant
DNA reagent
CD19-FcGamma CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot
Q96QR6_HUMAN) Extracellular antibody
sequence: V-L chain: aa 23–130
anti-CD19 CAR (Genbank AMZ04819) – GS
linker: ggtggcggtggctcgggcggtggtgggtcgg
gtggcggcggatct – V-H chain: aa 148–267
anti-CD19 CAR (Genbank AMZ04819)
Stalk/Transmembrane: aa 138–206 CD8 (Uniprot
Q96QR6_HUMAN) Cytosolic sequence: aa
19–86 Mouse Fc ERG precursor (Uniprot
P20491 (FCERG_MOUSE)) Fluorophore: mGFP
Recombinant
DNA reagent
CD19-empty CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot
Q96QR6_HUMAN) Extracellular antibody
sequence: V-L chain: aa 23–130
anti-CD19 CAR (Genbank AMZ04819) – GS
linker: ggtggcggtggctcgggcggtggtgggtcggg
tggcggcggatct – V-H chain: aa 148–267
anti-CD19 CAR (Genbank AMZ04819)
Stalk/Transmembrane: aa 138–206 CD8 (Uniprot
Q96QR6_HUMAN) Cytosolic sequence:
basic linker NHRNRRR (nucleotide AACCACAGG
AACCGAAGACGT) Fluorophore: mGFP
Recombinant
DNA reagent
CD22-Megf10 CAR this paper Signal peptide: aa 1–21 CSF2R (Uniprot P15509
(CSF2R_HUMAN)) Extracellular antibody
sequence: aa 22–258 of translated JP
2016502512-A/1: M971 Chimeric Antigen
(Genbank HZ530416.1) Stalk/Transmembrane:
aa 138–206 CD8 (Uniprot Q96QR6_
HUMAN) Cytosolic sequence: aa 879–1147
Mouse Megf10 (Uniprot Q6DIB5 (MEG10_
MOUSE)) Fluorophore: mGFP
Recombinant
DNA reagent
CD22-empty CAR this paper Signal peptide: aa 1–21 CSF2R (Uniprot P15509
(CSF2R_HUMAN)) Extracellular antibody
sequence: aa 22–258 of translated JP
2016502512-A/1: M971 Chimeric Antigen
(Genbank HZ530416.1) Stalk/Transmembrane:
aa 138–206 CD8 (Uniprot Q96QR6_HUMAN)
Cytosolic sequence: basic linker NHRNRRR
(nucleotide AACCACAGGAACCGAAGACGT)
Fluorophore: mGFP
Recombinant
DNA reagent
CD19-MerTK CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot Q96QR6
_HUMAN) Extracellular antibody sequence:
V-L chain: aa 23–130 anti-CD19
CAR (Genbank AMZ04819) – GS linker: ggtg
gcggtggctcgggcggtggtgggtcgggtggcggcggatct –
V-H chain: aa 148–267 anti-CD19 CAR
(Genbank AMZ04819) Stalk/Transmembrane: aa
138–206 CD8 (Uniprot Q96QR6_HUMAN)
Cytosolic sequence: aa 519–994 Mouse MerTK
(Uniprot Q60805 (MERTK_MOUSE))
Fluorophore: mGFP
Recombinant
DNA reagent
CD19-Bai1 CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot
Q96QR6_HUMAN)Extracellular antibody
sequence: V-L chain:aa 23–130 anti-CD19
CAR (Genbank AMZ04819)– GS linker:
ggtggcggtggctcgggcggtggtgggtcgggtggcgg
cggatct – V-H chain: aa 148–267 anti-CD19
CAR (GenbankAMZ04819) Stalk/Transmembrane:
aa 138–206 CD8 (UniprotQ96QR6_HUMAN)
Cytosolic sequence: aa1188–1582 Mouse
Bai1 (Uniprot Q3UHD1 (BAI1_MOUSE))
Fluorophore: mGFP
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Recombinant
DNA reagent
CD19-CD3zeta CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot Q96QR6_
HUMAN) Extracellular antibody sequence:
V-L chain: aa 23–130 anti-CD19 CAR
(Genbank AMZ04819) – GS linker: ggtggcggtggctcg
ggcggtggtgggtcgggtggcggcggatct – V-H chain:
aa 148–267 anti-CD19 CAR (Genbank
AMZ04819) Stalk/Transmembrane: aa 138–206 CD8
(Uniprot Q96QR6_HUMAN) Cytosolic sequence:
aa 52–164, Human TCR CD3 zeta chain
(Uniprot P20963) Fluorophore: sfGFP
Recombinant
DNA reagent
CD19-PI3K CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot Q96QR6
_HUMAN) Extracellular antibody sequence:
V-L chain: aa 23–130 anti-CD19 CAR
(Genbank AMZ04819) – GS linker: ggtggcggtggct
cgggcggtggtgggtcgggtggcggcggatct – V-H chain:
aa 148–267 anti-CD19 CAR (Genbank
AMZ04819) Stalk/Transmembrane: aa 138–206 CD8
(Uniprot Q96QR6_HUMAN) Cytosolic
sequence: aa 500–534 Mouse CD19 (Uniprot
CD19_MOUSE) Fluorophore: mCherry
Recombinant
DNA reagent
CD19 tandem CAR this paper Signal peptide: aa 1–21 CD8 (Uniprot Q96QR6_
HUMAN) Extracellular antibody sequence: V-L
chain: aa 23–130 anti-CD19 CAR
(Genbank AMZ04819) – GS linker: ggtggcggtggctc
gggcggtggtgggtcgggtggcggcggatct – V-H chain:
aa 148–267 anti-CD19 CAR (Genbank
AMZ04819) Stalk/Transmembrane: aa 138–206 CD8
(Uniprot Q96QR6_HUMAN) Cytosolic sequence:
aa 500–534 Mouse CD19 (Uniprot CD19
_MOUSE) fused to aa 19–86 Mouse Fc ERG
precursor (FCERG_MOUSE) Fluorophore: mGFP
Recombinant
DNA reagent
GFP-CaaX this paper eGFP fused to a c terminal
CaaX targeting sequence: aaaatgtccaaggatggta
agaaaaagaagaagaagtcaaaaaccaagtgtgttatcatg
Recombinant
DNA reagent
mCherry-CaaX this paper mCherry fused to a c terminal
CaaX targeting sequence: aaaatgtccaaggatggt
aagaaaaagaagaagaagtcaaaaaccaagtgtgttatcatg
Recombinant
DNA reagent
OVA/p2a/mCherry-CaaX this paper Cytoplasmic Ovalbumin (UNIPROT:
SERPINB14)/p2 a site: GGAAGCGGAGCTACTAA
CTTCAGCCTGCTGAAGCAGGCTGGAGA
CGTGGAGGAGAACCCTGGACCT/followed by
mCherry fused to a c terminal CaaX targeting
sequence: aaaatgtccaaggatggtaagaaaaagaag
aagaagtcaaaaaccaagtgtgttatcatg
Peptide,
recombinant protein
His10-CD3 zeta Hui and Vale (2014)
PMID: 24463463
aa 52–164, Human TCR CD3 zeta chain
(Uniprot CD3Z_HUMAN) fused to Hisx10 tag
Peptide,
recombinant protein
His10-FcRV this paper aa 45–85, Human FcRV (Uniprot FCERG
_HUMAN) fused to Hisx10 tag
Peptide,
recombinant protein
SNAP-Syk tSH2 this paper aa 1–262, Mouse Syk (Uniprot KSYK_MOUSE)
with N-term SNAP tag
Peptide,
recombinant protein
His10-Lck Y505F Hui and Vale (2014)
PMID: 24463463
full length Human Lck with inhibitory Tyr 505
mutated to Phe (Uniprot LCK_HUMAN) fused
to Hisx10 tag
Antibody anti phospho-Tyrosine Santa Cruz PY20 1:100 IF primary
Antibody anti mouse IgG coupled to
Alexa Fluor 647
Thermo/Lifetech A21236 1:200 IF secondary
Antibody anti mouse CD11c coupled
to APC
BioLegend 117313 FACS
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Antibody anti mouse F4/80 coupled
to APC/Cy7
BioLegend 123117 FACS
Other DMEM Gibco 11965–092
Other Pen-Strep-Glutamine Corning 30–009 Cl
Other Fetal Bovine Serum (FBS) Atlanta Biologicals S1150H
Other RPMI Gibco 11875–093
Other HEPES Gibco 1530080
Other 2-Mercaptoethanol Sigma M6250-100mL
Commercial
assay or kit
MycoAlert Mycoplasma
Testing Kit
Lonza LT07-318
Recombinant
DNA reagent
pMD2.G lentiviral
plasmid
other Addgene 12259 D. Stainier, Max Planck; VSV-G envelope
Recombinant
DNA reagent
pCMV-dR8.91 other Current Addgene
8455
Recombinant
DNA reagent
pHRSIN-CSGW other As cited James and Vale (2012),
PMID: 22763440
Other Lipofectamine LTX Invitrogen 15338–100 Lentivirus production
Other Lipofectamine Invitrogen 18324–012 Added to spin infections
to improve transduction
Other Hamilton Gastight
Syringes
Hamilton 8 1100
Other POPC Avanti 850457
Other Ni2+-DGS-NTA Avanti 790404
Other PEG5000-PE Avanti 880230
Other atto390 DOPE ATTO-TEC GmbH AD 390–161
Other PBS (Tissue Culture Grade) Gibco 20012050
Other Bioruptor Pico Diagenode Used for producing SUVs
Other 5 um silica microspheres Bangs SS05N
Peptide,
recombinant protein
CD19-His8 Sino Biological 11880H08H50
Peptide,
recombinant protein
CD22-His8 Sino Biological 11958H08H50
Other 2.5 um silica microspheres
(size titration)
Corpuscular C-SIO-2.5
Other 5 um silica microspheres
(size titration)
Corpuscular C-SIO-5
Other 10 um silica microspheres
(size titration)
Corpuscular C-SIO-10
Other 15 um silica microspheres
(size titration)
Corpuscular C-SIO-15
Other 20 um silica microspheres
(size titration)
Corpuscular C-SIO-20
Other Low retention tubes
for microsphere cleaning
Eppendorf 22431081
Other MatriPlate Brooks MGB096-1-2-LG-L
Peptide,
recombinant protein
M-CSF Peprotech 315–02
Other IMDM Thermo 12440079
Continued on next page
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Continued
Reagent type
(species)
or resource Designation Source or reference Identifiers Additional information
Other Retronectin Clontech T100A
Commercial
assay or kit
CD8 + T cell
purification kit
Stemcell 19853
Other eFluor670
proliferation dye
Thermo 65-0840-85
Chemical
compound, drug
phRSIN-CSGW Sigma L4516
Other Fluorobrite DMEM Gibco A1896701
Other DMEM minus phenol
red
Gibco A14430-01
Other Rhodamine PE Avanti 810150C
Other DOPS Avanti 840035C
Other SNAP-Cell 505-Star NEB S9103S
Other PD MiniTrap G-25 column GE Healthcare 28-9225-29 AB
Other 6.4% Paraformaldehyde
solution
Electron Microscopy
Sciences
50980495
Chemical
compound, drug
AlexaFluor 647 Phalloidin Thermo/Molecular Probes A22284
Software,
algorithm
ImageJ NIH
Software,
algorithm
Illustrator Adobe CC, CS6
Software,
algorithm
Photoshop Adobe CC, CS6
Software,
algorithm
Fiji https://fiji.sc/
Software,
algorithm
Prism GraphPad 7
Antibody anti human CD19
(mouse antibody)
OriGene TA506240 Clone
OTI2F6
IgG2a mouse monoclonal antibody
Antibody anti human CD47
(mouse antibody)
BD 556044 Clone
B6H12
IgG1 mouse monoclonal antibody
Antibody anti Ovalbumin
(rabbit antibody)
Pierce PA1-196 IgG rabbit polyclonal antibody
Constructs and antibodies
Detailed information for all constructs can be found in the Key resources table. This file includes the
following information for all receptors developed in this study: signal peptide, extracellular antibody
fragment, stalk/transmembrane domain, and cytosolic tail including appropriate accession numbers.
Antibodies used in this study are described in Supplemental Excel File 1, ‘Antibodies’ tab.
Cell culture
J774A.1 macrophages and NIH 3T3 fibroblasts were obtained from the UCSF cell culture facility and
cultured in DMEM (Gibco, Catalog #11965–092) supplemented with 1 x Pen-Strep-Glutamine (Corn-
ing, Catalog #30–009 Cl) and 10% fetal bovine serum (FBS) (Atlanta Biologicals, Catalog #S11150H).
Raji B cells were obtained from J. Blau (McManus lab, UCSF) and cultured in RPMI (Gibco, Catalog
#11875–093) supplemented with 1 x Pen-Strep-Glutamine (Corning, Catalog #30–009 Cl), 10% FBS
(Atlanta Biologicals, Catalog #S11150H), 10 mM HEPES (Gibco, Catalog #1530080), and 5 mM 2-
Mercaptoethanol (Sigma, Catalog #M6250-100mL). All cell lines used in this study were tested for
Mycoplasma at least once per month using the Lonza MycoAlert Detection Kit (Lonza, Catalog#
LT07-318) and control set (Lonza, Catalog #LT07-518).
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Lentivirus production and infection
Lentiviral infection was used to stably express CAR-P constructs in all cell types. Lentivirus was pro-
duced by HEK293T cells transfected with pMD2.G (a gift from Didier Tronon, Addgene plasmid #
12259 containing the VSV-G envelope protein), pCMV-dR8.91 (since replaced by second generation
compatible pCMV-dR8.2, Addgene plasmid #8455), and a lentiviral backbone vector containing the
construct of interest (derived from pHRSIN-CSGW) using lipofectamine LTX (Invitrogen, Catalog #
15338–100). The media on the HEK293T cells was replaced with fresh media 8–16 hr post transfec-
tion to remove transfection reagent. At 50–72 hr post-transfection, the lentiviral media was filtered
with a 0.45 mm filter and concentrated by centrifugation at 8000 x g for 4 hr or overnight. The con-
centrated supernatant was applied directly to ~0.5106 NIH 3T3 cells in 2 ml of fresh media. For
J77A4.1 macrophages and Raji B cells, the concentrated supernatant was mixed with 2 mls of media
and 2 mg lipofectamine (Invitrogen, Catalog # 18324–012) and added to the cells. The cells were
spun at 2200 x g for 45 min at 37˚C. Cells were analyzed a minimum of 72 hr later.
Preparation of CD19 and CD22 5 mm silica beads
Chloroform-suspended lipids were mixed in the following molar ratio using clean glasstight Hamilton
syringes (Hamilton, Catalog #8 1100): 97% POPC (Avanti, Catalog # 850457), 2% Ni2+-DGS-NTA
(Avanti, Catalog # 790404), 0.5% PEG5000-PE (Avanti, Catalog # 880230, and 0.5% atto390-DOPE
(ATTO-TEC GmbH, Catalog # AD 390–161). Lipid mixes were dried under argon and desiccated
overnight under foil. Dried lipids were resuspended in 1 ml tissue-culture grade PBS, pH7.2 (Gibco,
Catalog # 20012050), and stored under argon gas. Small unilamellar vesicles were formed by five
freeze-thaw cycles followed by 2  5 min of bath sonication (Bioruptor Pico, Diagenode), and
cleared by ultracentrifugation (TLA120.1 rotor, 35,000 rpm / 53,227 x g, 35 min, 4˚C) or by 33 freeze
thaw cycles. Lipid mixes were used immediately for form bilayers or shock frozen in liquid nitrogen
and stored under argon at  80˚C. To form bilayers on silica beads, 6  108 5 mm silica microspheres
(10% solids, Bangs Labs, Catalog # SS05N) were washed 2x in water, and 2x in PBS by sequential
suspension in water and spinning at 800 rcf, followed by decanting. Cleaned beads were resus-
pended in 150 ml tissue-culture grade PBS, pH7.2 (Gibco, Catalog # 20012050) and briefly vortexed.
30 ml cleared SUVs prepared as above as a 10 mM stock were added to bead suspension for a 2 mM
final SUV concentration. Beads were vortexed for 10 s, covered in foil, and rotated for 30 min at
room temperature to form bilayers. Bilayer-coated beads were washed 3x in PBS by sequential cen-
trifugation at 800 rcf and decanting. Beads were resuspended in PBS + 0.1% w/v BSA for blocking
for 15 min rotating at room temperature under foil. 10 nM final concentration of CD19his8 (Sino Bio-
logical, Catalog # 11880H08H50) or CD22his8 (Sino Biological, Catalog # 11958H08H50) protein
were added to blocked beads and proteins were allowed to bind during a 45 min incubation rotat-
ing under foil at room temperature. Beads were washed 3x in PBS + 0.1% w/v BSA by sequential
centrifugation at 300 rcf and decanting. Beads were resuspended in 120 ml PBS + 0.1% w/v BSA.
Preparation of CD19 silica beads over a range of diameters
Prior building bilayers on Silica beads ranging from 2.5 mm-20 mm in diameter (Microspheres-Nano-
spheres, Catalog# C-SIO-2.5, 5, 10, 15, 20), beads were RCA cleaned as follows: beads were pel-
leted at 2000 x g in low retention tubes (Eppendorf, Catalog #022431081) and resuspended in
acetone. Resuspended beads were sonicated for 60 min in a bath sonicator. Rinse and sonication
were repeated in ethanol. Finally, rinse and sonication were repeated in water. Beads were then
washed 2x in water to remove all traces of ethanol and left in a small volume after decanting. All fur-
ther steps were performed in a 70–80˚C water bath prepared in a fume hood. Proper Personal Pro-
tective Equipment (PPE) was worn throughout the RCA cleaning protocol. Washed beads were
added to 3 ml of hot 1.5 M KOH in a clean glass vial suspended in the water bath described above.
1 ml 30% H2O2 to bead solution and allowed to react for 10 min. Washed beads were cooled on ice,
pelleted at 2000xg and rinsed 5x in ultrapure water. Used cleaning solution was saved for disposal
by Environmental Health and Safety (EH and S). Cleaned beads were resuspended in 240 ml tissue-
culture grade PBS, pH7.2 (Gibco, Catalog # 20012050) and briefly vortexed. The lipid mix used in
this assay differed slightly from above. Here a mix of 93.5% POPC (Avanti, Catalog # 850457), 5%
Ni2+-DGS-NTA (Avanti, Catalog # 790404), 1% PEG5000-PE (Avanti, Catalog # 880230, and 0.5%
atto390-DOPE (ATTO-TEC GmbH, Catalog # AD 390–161. Bilayers were built and proteins coupled
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as described above. The concentration of CD19 was scaled appropriately to account for the
increased surface area of the larger beads.
Bead engulfment assay
12 to 16 hr prior to imaging, 2.5  104 J774A.1 macrophages expressing the appropriate CAR-P or
control construct were plated in a 96-well glass bottom MatriPlate (Brooks, Catalog # MGB096-1-2-
LG-L). To assess engulfment, 0.5  106 CD19 or CD22-ligated beads were added to each well.
Engulfment was allowed to proceed for 45 min at 37˚C incubator with CO2. Cells were then imaged
as described below.
Bites assay – J774A.1 macrophages, dendritic cells and NIH 3T3
fibroblasts
On the day of imaging 0.5  106 NIH 3T3 fibroblasts, dendritic cells or macrophages and 1.5 million
Raji B cells were combined in a 1.5 ml eppendorf tube and pelleted by centrifugation (800 rpm / 68
x g) for 5 min at room temperature. Culture media was decanted to ~100 ml volume and cells were
gently resuspended, and allowed to interact in the small volume for 60 min in a 37˚C incubator with
CO2. After incubation cells and beads were diluted to a final volume of 1000 ml and 300 ml of this co-
culture plated for imaging in a 96-well glass bottom MatriPlate (Brooks, Catalog # MGB096-1-2-LG-
L), and imaged as described below.
Eating assay read by FACS – J774A.1 macrophages and Raji B cells
20,000 J774A.1 macrophages were plated into 96-well glass bottom MatriPlate (Brooks, Catalog #
MGB096-1-2-LG-L) in a final volume of 300 ml complete DMEM (Gibco, Catalog #11965–092) supple-
mented with 1 x Pen-Strep-Glutamine (Corning, Catalog #30–009 Cl) and 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Catalog #S11150H). 52 hr prior to reading the assay macrophages were
stimulated with 500 ng/ml LPS (Sigma, Catalog # L4516). 44 hr prior to imaging LPS was removed
by three sequential gentle washes. After LPS removal 10,000 Rajis expressing mCherry-CAAX were
added to the well containing stimulated macrophages. The co-culture was incubated for 44 hr in a
37˚C tissue culture incubator with 5% CO2. After 44 hr, the remaining number of Raji B cells remain-
ing was analyzed by FACS as follows: 10,000 counting beads were added to the well immediately
prior to reading and the cell-counting bead mixture was harvested by pipetting up and down 8x
with a p200 pipet. The assay was read on an LSRII (BD Biosciences) and Rajis were identified by the
presence of mCherry fluorescence.
Primary cell transduction and differentiation
Bone marrow derived macrophages (BMDMs) were produced as previously described
(Weischenfeldt and Porse, 2008), except that L-929 conditioned media was replaced with purified
25 ng/ml M-CSF (Peprotech, Catalog # 315–02). The BMDMs were lentivirally infected with concen-
trated lentivirus after 5 days of differentiation. Differentiation was confirmed by F4/80 staining on
day seven and found to be >95% efficient for each replicate. Phagocytosis was measured on day
nine in imaging media lacking M-CSF.
To produce CAR-P expressing dendritic cells, bone marrow-derived hematopoietic stem cells
were lentivirally infected immediately after harvest by spinning with concentrated lentivirus in
GMCSF-containing media (IMDM supplemented with 10% FBS and PSG) on retronectin (Clontech,
Catalog # T100A)-coated plates at 2200 x g for 45 min at 37˚C. Dendritic cells were produced as
previously described (Mayordomo et al., 1995) by culturing bone marrow cells for 8–11 days with
GMCSF. IL-4 was added 2–3 days before use. Efficient differentiation into CD11c + dendritic cells
was verified by FACS, revealing 95% APC-CD11c + cells (Biolegend, Catalog #N418).
Antigen cross-presentation assay
The ability of CAR-P to stimulate OTI T cell proliferation was tested using the co-culture assay shown
as a schematic in Figure 4—figure supplement 4 and described previously (Roberts et al., 2016).
10,000 CAR-P transduced CD11c + dendritic cells transduced and differentiated as above were
plated in U bottom 96 well dishes (Falcon, Catalog #353077) and stimulated with 1 ug/ml LPS. 12 hr
after LPS stimulation, 40,000 Raji B cells expressing soluble cytosolic ovalbumin (Raji B-OVA) were
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added to the culture. 24 hr after Raji B-OVA cell addition, 50,000 OTI CD8 + T cells isolated from
lymph nodes of OTI TCR transgenic mice using a CD8 +T cell purification kit (Stemcell, Catalog
#19853) and labeled with e670 proliferation dye (Thermo, Catalog #65-0840-85) were added. 72 hr
after OTI addition the percent of OTI cells divided was measured by eFluor670 signal using flow
cytometry.
Confocal imaging
All imaging in this study was performed using a spinning disk confocal microscope with environmen-
tal control (Nikon Ti-Eclipse inverted microscope with a Yokogawa spinning disk unit). For bead
internalization assays, images were acquired using a 40  0.95 N/A air objective and unbiased live
image acquisition was performed using the High Content Screening (HCS) Site Generator plugin in
mManager3. Other images were acquired using either a 100  1.49 N/A oil immersion objective. All
images were acquired using an Andor iXon EM-CCD camera. The open source mManager software
package was used to control the microscope and acquire all images3.
Quantification of whole cell internalization
20,000 J774A.1 macrophages were plated into 96-well glass bottom MatriPlate (Brooks, Catalog #
MGB096-1-2-LG-L). Four hours prior to imaging, the macrophages were stimulated with 500 ng/ml
LPS (Sigma, Catalog # L4516). Immediately prior to imaging the LPS-containing media was replaced
with Fluobrite DMEM (ThermoFisher Scientific, Catalog # A1896701) containing 10% FBS. 40,000
Raji cells were added to the macrophages and the co-culture was imaged at 5 min intervals for 12
hr. For the antibody experiments, macrophages were washed into DMEM minus phenol red
(A14430-01) containing 10% FBS just prior to addition of 40,000 Raji cells. Where indicated antibody
was added to a final concentration of 20 mg/ml immediately after Raji cell addition and prior to
imaging to limit antibody internalization. Because cells moved in and out of the field of view, we
selected the cells present after 8 hr of imaging and quantified their B cell eating if they could be fol-
lowed for four hours or more. Time-lapse analysis was essential to ensure that the B cell appeared
viable prior to engulfment by the macrophage. Engulfment of B cells with an apoptotic morphology
was not counted as a whole cell eating event.
Quantification of bites internalization
During live cell image acquisition GFP-positive J774A.1 macrophages or NIH 3T3 cells were selected
by the presence of GFP signal. A full z-stack comprising the entire cell was captured using 1 mm
steps. All z sections were then manually inspected for internalized Raji B cell material. Cells contain-
ing one or more bites of fully internalized Raji B cell material >1 mm in diameter were scored as
positive.
Liposome FRET assay
Experiments were carried out as previously described2. Briefly, proteins were purified using a bacte-
rial expression system. All protein components (1 mg/ml BSA, 100 nM tSH2-Syk SNAP-505, 0 to 500
nM His10-CD3z or His10-FcRV intracellular chain, and 7.2 nM His10-Lck Y505F) were mixed into
kinase buffer (50 mM HEPES-NaOH pH 6.8, 150 mM NaCl, 10 mM MgCl2, and 1 mM TCEP). Lipo-
somes prepared at the following molar ratios: 74.5% POPC (Avanti, Catalog # 850457C), 10%
DOGS-NTA (Nickel) (Avanti, Catalog # 790404C, 0.5% Rhodamine PE (Avanti, Catalog # 810150C),
and 15% DOPS (Avanti, Catalog # 840035C) were added and the mixture was incubated for 40–60
min at room temperature, during which the SNAP-505 fluorescence was monitored at 8 s intervals
with 504 nm excitation and 540 nm emission. 1 mM ATP was then injected to trigger Lck mediated
phosphorylation of CD3z or FcRV. Injection was followed by 5 s of automatic shaking of the plate,
and the fluorescence was further monitored at 8 s intervals for at least 1 hr. Data were normalized
by setting the average fluorescence value of the last 10 data points before ATP addition as 100%
and background fluorescence as 0%. The final extent of fluorescence quenching (% fluorescence
change) at each concentration of receptor was determined using the average of the last 20 data
points after ensuring fully equilibrated binding. Nine reactions containing increasing concentrations
of CD3z and nine reactions containing increasing concentrations of FcRV were run in parallel. The
final % fluorescence change was plotted against FcRV or CD3z concentration. The apparent
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dissociation constants (Kd) of tSH2-Syk to FcRV and CD3z were calculated by fitting the data with
Graphpad Prism 6.0, using the ‘one site specific binding’ model.
Protein expression, purification, and labeling
The intracellular portion of the FcR g-chain (aa 45–85, Human FcRV, Uniprot FCERG_HUMAN) was
cloned into a modified pET28a vector containing a His10 upstream to the multiple cloning site using
BamHI and EcoRI. The intracellular portion of CD3z (aa 52–164, Human CD3z, Uniprot CD3Z_HU-
MAN) was also cloned into the His10 modified pET28a vector. A Lys-Cys-Lys-Lys sequence, originally
present for fluorescent labeling, is also present between His10 and CD3z in this construct. SNAP-
tSH2Syk (aa 1–262) was cloned into a pGEX6 vector using BamHI and EcoRI. His10-CD3z, His10-FcR
g-chain, and GST-SNAP-tSH2Syk were bacterially expressed in BL21 (DE3) RIPL strain of Escherichia
coli as described previously2. His10-Lck Y505F was expressed in SF9 cells using the Bac-to-Bac bacu-
lovirus system as described previously2. All cells were lysed in an Avestin Emulsiflex system. His10
proteins were purified by using Ni-NTA agarose (Qiagen, Catalog # 30230) and GST-SNAP-tSH2Syk
was purified by using glutathione-Sepharose beads (GE Healthcare, Catalog # 17075601) as
described previously2. Soluble SNAP-tSH2 Syk was generated by cleaving the GST moiety via the
PreScission Protease at 4˚C overnight. All proteins were subjected to gel-filtration chromatography
using a Superdex 200 10/300 GL column (GE Healthcare, Catalog # 17517501) in HEPES-buffered
saline (HBS) containing 50 mM HEPES-NaOH (pH 6.8 for His10-CD3z, His10-FcR g-chain, and GST-
SNAP-tSH2Syk and pH 7.4 for His10-Lck Y505F), 150 mM NaCl, 5% glycerol, and 1 mM TCEP. The
monomer fractions were pooled, frozen in liquid nitrogen and stored at  80˚C. All gel-filtered pro-
teins were quantified by SDS-PAGE and Coomassie staining, using BSA as a standard. To prepare
fluorescently labeled tSH2 Syk, 10 uM SNAP-tSH2 Syk was incubated at a 1:2 ratio with SNAP-Cell
505-Star (NEB, Catalog # S9103S) overnight at 4˚C and run over a PD MiniTrap G-25 (GE Healthcare,
Catalog # 28-9225-29 AB) column to eliminate excess dye.
Phosphotyrosine and phalloidin staining
To fix and stain preparations described above in bead and bites assays for quantifying enrichment of
phosphotyrosine staining, half the media (~150 ml) was gently removed from the imaging well and
replaced with 150 ml 6.4% paraformaldehyde solution (prepared from 32% stock, Electron Micros-
copy Sciences, Catalog # 50980495) in tissue culture grade PBS, pH7.2 (Gibco, Catalog #
20012050). Cells were fixed for 15 min in a 37˚C incubator with CO2. After fixation cells were washed
2x with PBS and permeabilized/blocked for 60 min at room temperature in freshly prepared, filter
sterilized PBS + 5% FBS+0.1% w/v saponin (PFS solution). After permeabilization, cells were washed
2  3 min with PFS solution. Following block, cells were incubated with 1:100 dilution of mouse anti-
phosphotyrosine (pTyr) antibody to stain pan-pTyr (Santa Cruz, Catalog # PY20) diluted in PFS solu-
tion in the dark for 60 min at room temperature then washed 3  5 min in PFS solution. Washed cells
were incubated with a 1:500 dilution of goat anti-mouse Alexa Fluor 647 antibody (Thermo/Molecu-
lar Probes, Catalog # A21236) in PFS solution in the dark for 60 min at room temperature. Wells
were then washed 3  5 min in PFS solution. Cells were covered in 200 ml PBS. If not imaged imme-
diately samples were wrapped in parafilm and foil and stored at 4˚C prior to microscopy. Phospho-
tyrosine enrichment at the synapse was calculated by dividing the mean Alexa Fluor 647 signal of a 5
pixel linescan at the synapse with bead or cell by a 5 pixel linescan on the cortex. For phalloidin
staining, cells were fixed with 4% PFA for 15 min at room temperature, blocked and permeabilized
with 5% BSA in TBS with 0.5% triton X overnight, and incubated with AlexaFluor 647 Phalloidin
(Thermo/Molecular Probes, Catalog # A22284) for 20 min. Cells were then washed with PBS, imaged
and quantified using the method described above. Each data point represents a single cell, and the
graphs reflect pooled results from three biological replicates.
Ovalbumin antibody staining
To fix and stain preparations described above for ovalbumin staining, half the media (~150 ml) was
gently removed from the imaging well and replaced with 150 ml 8% paraformaldehyde solution (pre-
pared from 32% stock, Electron Microscopy Sciences, Catalog # 50980495) in tissue culture grade
PBS, pH7.2 (Gibco, Catalog # 20012050). Cells were fixed for 10 min in a 37˚C incubator with CO2.
After fixation cells were washed 2x with PBS and permeabilized/blocked for 60 min at room
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temperature in freshly prepared, filter sterilized PBS + 0.1% w/v casein +0.1% w/v saponin (PCS solu-
tion). After permeabilization, cells were washed 1  3 min with PCS solution and blocked for 1 hr at
room temperature in PCS. Following block, cells were incubated with 1:100 dilution of rabbit anti-
ovalbumin (OVA) antibody to stain OVA (Thermo/Pierce, Catalog # PA1-196) diluted in PCS solution
overnight at 4˚C. Washed cells were incubated with a 1:200 dilution of goat anti-rabbit Alexa Fluor
647 antibody (Thermo/Molecular Probes, Catalog # A21235) and 3.3 nM 488 phallodin (dissolved at
6.6 mM in methanol) in PCS solution in the dark for 60 min at room temperature. Wells were then
washed 3  5 min in PCS solution. Cells were covered in 200 ml PBS and immediately imaged. Oval-
bumin signal was quantified as the corrected total cell fluorescence (CTCF). CTCF = Integrated Den-
sity – Area of Selected Cell * Mean Fluorescence of 3 Background Readings. Each data point
represents a single cell, and the graphs reflect pooled results from three biological replicates.
Image processing and analysis
All image quantification was done on raw, unedited images. All images in figures were first analyzed
in ImageJ, where a single Z-slice at the center of the cell was extracted. The image intensities were
scaled to enhance contrast and cropped in Photoshop. For movies, background was subtracted in
Fiji using a rolling ball radius of 50 mm and bleach corrected using the Histogram Matching plug in.
Statistics
All statistical analysis was performed in Prism 6.0 (GraphPad, Inc.). The statistical test used is indi-
cated in each figure legend. Error bars throughout the paper denote 95% confidence intervals of the
mean. *** indicates p<0.0001; ** indicates p<0.001 and * indicates p<0.01.
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